The Edaravone treatment is commonly used for Amyotrophic Lateral Sclerosis (ALS), a progressive condition often referred to as Lou Gehrig's disease. Its therapeutic goal is to help moderate the progressive loss of function associated with the condition.

The medicine is commonly used for managing ALS, a condition characterized by progressive deterioration of voluntary muscle control and strength. The medicine is generally applied when symptoms become more noticeable in adult patients who are still functionally independent. The therapeutic benefit contributes to supporting a patient's ability to maintain routine, day-to-day functioning, such as walking and self-care, by addressing symptoms that interfere with daily functioning.

“The treatment is relevant for providing supportive care that may help patients cope more steadily with symptom fluctuations and supports general well-being.”

This approach provides support that helps ease the overall symptom burden by helping patients preserve their existing physical capabilities for a longer duration. This ultimately assists with maintaining functional stability and supports overall well-being.

---

Quick Fact: Support for Progressive Functional Decline The medicine is commonly used to help with symptoms related to the loss of muscle function, which may be part of symptomatic management in ALS. It is considered relevant for managing symptoms associated with the loss of autonomy.

Edaravone eligibility is defined by official regulatory criteria, primarily applying to adult patients with Amyotrophic Lateral Sclerosis (ALS).

Contraindications and Restrictions

Classification	Rule (Official Regulatory Statement)
Absolute Contraindication	Patients with a history of hypersensitivity to edaravone or any of the product's inactive ingredients.
Condition-Specific Caution	Edaravone contains sodium bisulfite, which may trigger allergic-type reactions, including severe asthmatic episodes or anaphylaxis, particularly in individuals with known sulfite sensitivity or asthma.
Pediatric Use	Safety and effectiveness have not been established in pediatric patients (under 18 years).
Pregnancy and Lactation	Use during pregnancy is generally not recommended as animal studies suggest potential fetal harm; the presence of edaravone in human breast milk is unknown, and the drug was detected in rat milk.
Hepatic/Renal Impairment	The effects of severe hepatic or renal impairment on the drug's pharmacokinetics have not been studied.

Eligibility is limited to the adult population based on the lack of safety data in children and the defined contraindications. Regulatory documents classify hypersensitivity as an absolute reason to prohibit use.

Interactions with other medicines and products

Edaravone's official interaction profile is defined primarily by a lack of clinically significant drug-drug interactions and specific administrative requirements. The drug is largely eliminated through conjugation rather than by major Cytochrome P450 (CYP) enzymes.

---

Pharmacokinetic Interaction Profile

• Medicinal product categories with documented interactions: None are formally documented in official prescribing information as having clinically significant pharmacokinetic interactions.
• Mechanistic basis of interactions: Edaravone and its metabolites are not expected to be significant inhibitors or inducers of major CYP enzymes (e.g., CYP3A4, CYP2D6) or UGT isoforms. The lack of effect on these pathways means co-administration with modulators of these enzymes is not predicted to alter Edaravone exposure.
• Transporter Effects: The primary metabolite, Edaravone sulfate, is documented to inhibit the OAT3 (Organic Anion Transporter 3) transporter. However, the regulatory documentation classifies the clinical significance of this effect on co-administered OAT3 substrates as unknown.

---

Food and Administration-Timing Constraints

• Timing-based interaction rules: The oral suspension formulation requires strict timing relative to food intake. The dose must be administered in the morning after overnight fasting, and food must not be consumed for one hour after administration. This is a mandatory requirement to maintain established drug exposure.
• IV Compounding Restriction: For the intravenous solution, a critical procedural constraint applies: other medications must not be injected into the infusion bag or mixed with Edaravone to prevent potential physicochemical incompatibility.

Edaravone functions as a free radical scavenger targeting reactive oxygen species (ROS), including the hydroxyl radical (cdotOH) and peroxynitrite ( ONOO^-). Due to its amphiphilicity, the molecule readily crosses the blood-brain barrier and cell membranes, interacting with both lipid- and water-soluble radicals within the central nervous system and peripheral tissues.

The primary mechanism involves Edaravone donating an electron to the radical species, thereby stabilizing and neutralizing the reactive intermediate. This reduction-oxidation interaction is non-specific across multiple radicals, classifying Edaravone as an antioxidant. At the molecular level, this action inhibits lipid peroxidation, a chain reaction that damages cellular components, including the unsaturated fatty acids of neuronal cell membranes. Intracellularly, the scavenging activity limits oxidative stress, which contributes to the preservation of mitochondrial membrane potential and cellular integrity. A secondary, non-radical scavenging interaction involves binding to the Aryl Hydrocarbon Receptor (AHR), triggering its nuclear translocation. This activation promotes the downstream upregulation of the Nuclear factor erythroid 2-related factor 2 (NRF2) signaling pathway, which is a master regulator of endogenous cytoprotective and antioxidant gene expression. System-level physiological modulation consequently involves reduced oxidative damage to neurons and glia, attenuating processes that compromise cellular viability.

How to Use Edaravone

Edaravone is administered according to a highly specific, standardized dosing regimen that utilizes repetitive 28-day treatment cycles. This pattern is consistent for both approved routes of administration: as an intravenous (IV) infusion and as an oral suspension.

---

Administration Guidelines

Feature	Detail
Route of Administration	Intravenous (IV) Infusion or Oral (by mouth), including via feeding tubes.
Standard Daily Dose	60 mg (IV) or 105 mg (Oral).
Infusion Duration	The IV dose is administered over 60 minutes.
Frequency Pattern	Daily dosing during specific periods within the 28-day cycle.
Fasting Requirements	The oral suspension must be taken in the morning on an empty stomach, followed by a 1-hour fast.

---

Treatment Cycle Structure

Treatment begins with an Initial Cycle and continues with subsequent cycles. The standard use protocol dictates distinct periods of administration and drug-free intervals:

• Initial Cycle: The standard daily dose is administered for 14 consecutive days, followed by a 14-day drug-free period.
• Subsequent Cycles: The standard daily dose is administered for 10 days out of a 14-day period, which is then followed by a 14-day drug-free period to complete the 28-day cycle.

No specific dose adjustments are typically required for older adults or for patients with mild to moderate renal or hepatic impairment. If a dose of the oral suspension is missed, the patient should take the next scheduled dose; two doses must not be taken on the same day.

Research evidence / Overview of studies for Edaravone Pfizer

Evidence for Use in Amyotrophic Lateral Sclerosis (ALS)

Research into Edaravone was evaluated in studies examining daily-life functioning for individuals with Amyotrophic Lateral Sclerosis (ALS), a condition marked by functional limitations. The core evidence includes short-term randomized, placebo-controlled clinical trials (RCTs), where the medicine was studied against an inactive substance. These studies explored outcomes reflecting daily functioning or activity level. Researchers primarily focused on functional measures, including the rate of functional decline, which was one of the core measures used, alongside the Revised ALS Functional Rating Scale (ALSFRS-R) score. In one specific short-term RCT, research examined measurements on the ALSFRS-R and observed patterns that varied between the treatment group and the placebo group.

Measuring Functional Changes and Survival in Studies

In the short-term controlled studies, the primary research examined how symptoms evolved in the observed populations during the defined time intervals. Initial studies exploring the broader ALS population reported inconsistent patterns of functional outcome. Later research focusing on an enriched subgroup of patients—those with a shorter history of ALS and a higher level of function—indicated patterns that were different from those reported in the initial, broader trials. These studies provided insight into short-term changes in daily functioning. Research also monitored specific biomarkers measured in the blood.

Long-Term Evidence and Real-World Follow-up

The controlled studies have limited information for long-term outcomes, as their follow-up durations were limited to six months. To supplement this, research examined long-term outcomes using observational data. Evidence derived from these observational settings examined outcomes related to overall survival in those associated with the use of the medicine. However, the certainty remains low when compared to the initial short-term RCTs. Long-term effects are not fully established under controlled conditions.

Study Populations and Applicability of Research

Key evidence was derived from a highly selective patient population. This enriched subgroup was defined by criteria such as shorter disease duration and relatively preserved functional and respiratory capacity at the study start. The use of this specific patient group means research on the findings for the wider ALS population remains insufficient, including those with more advanced disease or lower respiratory capacity.

What is Still Uncertain About the Research for Edaravone Pfizer

The short duration of the primary randomized controlled trials means that long-term functional outcomes are not fully established using controlled methods. Furthermore, because the key findings apply only to the enriched populations studied, there is limited information for long-term outcomes for patients outside of those narrow criteria.

Common questions about Edaravone Pfizer (FAQ)

---

Q: What is the difference between Edaravone IV infusion and the oral suspension?

The medicine is available as an intravenous (IV) infusion and an oral suspension taken by mouth. According to regulatory documents, the oral dose is higher (105 mg) than the IV dose (60 mg). This difference in amount is to achieve a similar level of the medicine's exposure in the body, as defined by specialized studies.

---

Q: Can Edaravone be used alongside Riluzole?

Official information indicates that Edaravone is not expected to have significant interactions with most other medicines because it does not significantly affect the body's major drug-metabolizing enzymes. The fact that the clinical trials did not require stopping Riluzole indicates that co-administration was observed during the studies that led to approval.

---

Q: What are the general expectations about when a patient might notice an effect?

The primary clinical studies that provided evidence for the medicine's effects were six months in duration, with researchers examining changes in functional ability during that time. Official regulatory documents do not specify a particular time frame for when an individual patient may perceive a change in their condition.

---

Q: How quickly is Edaravone eliminated from the body?

According to pharmacokinetic studies, the amount of time it takes for half of the medicine to be eliminated from the body, known as the terminal elimination half-life, is described as approximately 4.5 to 9 hours after administration.

---

Q: What is the half-life of Edaravone's main breakdown products (metabolites)?

The body breaks down Edaravone into chemical compounds called metabolites, which are not thought to be pharmacologically active. The official information describes the half-lives of these main breakdown products as ranging from 3 to 6 hours.

---

Q: Does Edaravone interact with vitamins or nutritional supplements?

The official interaction profile indicates that Edaravone does not generally cause problems with other medications because it is not expected to significantly interfere with the major drug-metabolizing pathways. The regulatory documents do not specifically list vitamins or supplements as being known to interact with the medicine.

---

Q: Is Edaravone an actual cure for the condition it treats?

Regulatory and authoritative sources indicate that the condition Edaravone is indicated for is a progressive and currently incurable neurodegenerative disease. Official materials state that Edaravone has been shown in some studies to slow the rate of functional decline, but it is not described as a cure.

---

Q: What kind of benefits did clinical research show for Edaravone?

Results from clinical trials indicated a slower decline of functional ability in daily activities, such as those measured by the Revised ALS Functional Rating Scale (ALSFRS-R) score. This finding was observed in a specific, limited subgroup of patients studied in a randomized controlled trial.

---

Q: Can people with liver problems use Edaravone?

According to official product information, patients with mild or moderate liver problems do not typically require a dose change. However, the effects of the medicine have not been studied in patients with severe liver impairment, meaning there is no official information regarding the use of Edaravone in this population.

---

Q: What is the typical length of time a patient might stay on Edaravone treatment?

The medicine is administered in repetitive 28 -day treatment cycles according to a fixed schedule. Although the initial controlled studies were only six months long, treatment is commonly continued beyond that period, as official prescribing information does not define a maximum treatment length.

---

Q: What should a patient do if they accidentally miss a dose of the oral suspension?

The official product instructions specify the rule for managing a missed dose of the oral suspension. The rule is to take only the next scheduled dose and to avoid taking two doses on the same day.

---

Q: Are there any dietary restrictions related to taking the Edaravone oral suspension?

The oral suspension is subject to a strict timing rule relative to food intake. Specifically, the requirement is that it is administered on an empty stomach after overnight fasting, and food (other than water) is not consumed for one hour afterward.

---

Q: Where does Edaravone treatment typically take place (home, clinic, or hospital)?

The oral suspension formulation is designed for patient self-administration in the home setting. The intravenous infusion may be administered by a healthcare professional in a clinic, hospital, or, in some regions, in a home setting.

---

Q: Is there any known link between Edaravone and liver function?

Official information indicates that Edaravone has not been associated with acute, clinically noticeable liver injury. While patients with mild to moderate liver problems do not require a dose change, the safety and effectiveness in people with severe liver impairment have not been formally studied.

---

Q: Can Edaravone affect blood sugar levels?

One of the common adverse reactions reported in clinical trials is Glycosuria, which refers to having sugar in the urine. However, the official prescribing information does not provide additional details about the direct impact of the medicine on a patient's overall blood sugar levels or diabetic control.

---

Q: What distinguishes Edaravone from the initial FDA-approved drug for the condition it treats?

Edaravone is classified as an antioxidant that works as a free radical scavenger to help reduce oxidative stress in the body. The initial FDA-approved drug for this condition, Riluzole, is an agent believed to act primarily by affecting glutamate, representing a distinct difference in mechanism of action.

---

Q: Are there any research initiatives currently studying Edaravone's long-term effects?

Yes. Beyond the initial short-term controlled studies, ongoing postmarketing safety analyses and long-term observational follow-up studies are conducted by researchers. These initiatives monitor the medicine's safety and effects over a longer period than the original clinical trials.

---

Q: Has Edaravone been tested for use in children under 18?

The regulatory documents state that the safety and effectiveness of the medicine have not been established in the pediatric population (patients under 18 years). Therefore, its use is currently not indicated for this age group.

---

Q: Can Edaravone be administered in a non-clinical setting, like at home?

The oral suspension formulation allows for administration by the patient at home. The intravenous infusion may also be administered in a non-clinical setting, such as the home, depending on local health care provider instructions and protocols.

Official Storage and Disposal Requirements

Edaravone must be stored according to specific regulatory mandates to maintain its stability and integrity, as defined by government health authorities.

Storage Conditions

Product Form	Temperature Range	Special Protection
Injection	20°C to 25°C (Controlled Room Temperature)	Protect from light; store in overwrapped package to protect from oxygen.
Oral Suspension (Patient Storage)	20°C to 25°C (Room Temperature)	Protect from light; store upright; do not freeze.

Stability and Handling

• The injection must be used within 24 hours after its overwrap package is opened.
• The Oral Suspension bottle must be discarded either 15 days after opening or 30 days from the pharmacy shipment date, whichever is earlier.
• The oral suspension container is supplied with a child-resistant closure and must be kept out of the reach of children.

Disposal Rules

Unused or expired medication must be discarded according to local regulations. Regulatory documents prohibit discharging the product to sewer systems and advise against release to the environment.